Entinostat in patients with relapsed or refractory abdominal neuroendocrine tumors.

Jamison JK, Zhou M, Gelmann EP, Luk L, Bates SE, Califano A, Fojo T

DOI: 10.1093/oncolo/oyae118
Published: 2024 Sep 6
Container: The oncologist
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1093/oncolo/oyae118,
  title = {Entinostat in patients with relapsed or refractory abdominal neuroendocrine tumors.},
  author = {Jamison JK and Zhou M and Gelmann EP and Luk L and Bates SE and Califano A and Fojo T},
  year = {2024},
  journal = {The oncologist},
  doi = {10.1093/oncolo/oyae118},
  url = {https://doi.org/10.1093/oncolo/oyae118}
}

RIS

TY  - JOUR
TI  - Entinostat in patients with relapsed or refractory abdominal neuroendocrine tumors.
AU  - Jamison JK
AU  - Zhou M
AU  - Gelmann EP
AU  - Luk L
AU  - Bates SE
AU  - Califano A
AU  - Fojo T
PY  - 2024
JO  - The oncologist
DO  - 10.1093/oncolo/oyae118
UR  - https://doi.org/10.1093/oncolo/oyae118
ER  -

APA

JK, J., M, Z., EP, G., L, L., SE, B., A, C., & T, F. (2024). Entinostat in patients with relapsed or refractory abdominal neuroendocrine tumors.. The oncologist. https://doi.org/10.1093/oncolo/oyae118

Source records

pubmed · retrieved 2026-09-27T10:41:39.861Z